Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 5:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hormone Sensitive Prostate Cancer Clear all
Completed Phase 2 Interventional Results available

CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone

NCT03934840
View directory record Official record
Conditions
Prostate Cancer
Interventions
Cabazitaxel, Carboplatin, Abiraterone, Prednisone
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older · Male only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
8
States / cities
Phoenix, Arizona • Chicago, Illinois • New Orleans, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 29, 2026, 5:59 AM EDT
Recruiting Phase 2 Interventional

Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer

NCT07216248
View directory record Official record
Conditions
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Interventions
relugolix + ARPI., Intermittent- Relugolix or androgen deprivation therapy (ADT) + ARPI, relugolix or androgen deprivation therapy (ADT) + ARPI
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Male only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 29, 2026, 5:59 AM EDT
Completed No phase listed Observational Results available

A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

NCT06072196
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Novel hormonal therapy
Drug
Lead sponsor
Pfizer
Industry
Eligibility
65 Years and older · Male only
Enrollment
3,017 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Sep 29, 2026, 5:59 AM EDT
Completed No phase listed Observational

Survey Based Discrete Choice Experiment Study in Prostate Cancer (DECIDER) Study

NCT05381311
View directory record Official record
Conditions
Prostate Cancer, Metastatic Hormone-sensitive Prostate Cancer
Interventions
Not listed
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,020 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Sep 29, 2026, 5:59 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC

NCT02489318
View directory record Official record
Conditions
Prostate Cancer
Interventions
Apalutamide, Placebo, Androgen Deprivation Therapy (ADT)
Drug
Lead sponsor
Aragon Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,052 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
39
States / cities
Homewood, Alabama • Tucson, Arizona • San Bernardino, California + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2026 · Synced Sep 29, 2026, 5:59 AM EDT
Recruiting Phase 1Phase 2 Interventional

TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT07190300
View directory record Official record
Conditions
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Interventions
Tulmimetostat, Darolutamide, Abiraterone
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
8
States / cities
Birmingham, Alabama • Iowa City, Iowa • Westwood, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 29, 2026, 5:59 AM EDT
Withdrawn Phase 2 Interventional

Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone

NCT06060587
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, ADT, Abiraterone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Sep 29, 2026, 5:59 AM EDT
Active, not recruiting Phase 2 Interventional

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

NCT06734130
View directory record Official record
Conditions
Metastatic Castration Sensitive Prostate Cancer
Interventions
Luteinizing Hormone-Releasing Hormone (LHRH) analog, Androgen Receptor Signal Inhibitor (ARSI), Docetaxel
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 29, 2026, 5:59 AM EDT
Completed Phase 1 Interventional

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

NCT04477512
View directory record Official record
Conditions
Metastatic Hormone Refractory Prostate Cancer
Interventions
Cabozantinib, Nivolumab, Abiraterone acetate, Prednisone, Peripheral blood collection
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Sep 29, 2026, 5:59 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

NCT02319837
View directory record Official record
Conditions
Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
Interventions
Enzalutamide, Placebo (No longer applicable in Open Label study period), Leuprolide Open Label
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,068 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
77
States / cities
Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 29, 2026, 5:59 AM EDT
Completed Phase 2 Interventional Results available

Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer

NCT01120236
View directory record Official record
Conditions
Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Interventions
Bicalutamide, Cixutumumab, Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide Acetate, Pharmacological Study
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
169
States / cities
Fairbanks, Alaska • Little Rock, Arkansas • Rogers, Arkansas + 117 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2018 · Synced Sep 29, 2026, 5:59 AM EDT
Recruiting Phase 1 Interventional

JUR-003 in Adult Patients With Metastatic Prostate Cancer

NCT07824349
View directory record Official record
Conditions
Metastatic Castration Resistant Prostate Cancer, Oligometastatic Prostate Cancer (OMPC), Metastatic Hormone Sensitive Prostate Cancer
Interventions
JUR-003
Biological
Lead sponsor
Juri Biosciences, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Grand Rapids, Michigan • Lake Success, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 29, 2026, 5:59 AM EDT
Completed Phase 2 Interventional

Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer

NCT03860987
View directory record Official record
Conditions
Castrate Sensitive Prostate Cancer
Interventions
goserelin, Enzalutamide, Abiraterone, 18F-DCFPyL, Prednisone, Radical Prostatectomy
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 29, 2026, 5:59 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies

NCT05794906
View directory record Official record
Conditions
Biochemically Recurrent Prostate Cancer
Interventions
Darolutamide (BAY1841788, Nubeqa), Placebo matching darolutamide, ADT
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
985 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
25
States / cities
Phoenix, Arizona • Duarte, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 29, 2026, 5:59 AM EDT
Active, not recruiting Not applicable Interventional

INTense ExeRcise for SurviVAL Among Men with Metastatic Prostate Cancer (INTERVAL - GAP4)

NCT02730338
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
High intensity aerobic and resistance training, Psychosocial support
Behavioral
Lead sponsor
Movember Foundation
Other
Eligibility
18 Years and older · Male only
Enrollment
866 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Sep 29, 2026, 5:59 AM EDT
Completed Phase 3 Interventional Results available

A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

NCT02677896
View directory record Official record
Conditions
Metastatic Hormone Sensitive Prostate Cancer
Interventions
Enzalutamide, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
34
States / cities
Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Sep 29, 2026, 5:59 AM EDT
Recruiting Phase 2 Interventional

Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer

NCT05915442
View directory record Official record
Conditions
Oligometastatic Prostate Cancer
Interventions
Quemliclustat, Etrumadenant, Zimberelimab, Stereotactic Body Radiation Therapy
Drug · Radiation
Lead sponsor
Catherine Spina
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 19, 2025 · Synced Sep 29, 2026, 5:59 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

NCT05288166
View directory record Official record
Conditions
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
Interventions
Abemaciclib, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
925 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
63
States / cities
Prescott, Arizona • Prescott Valley, Arizona • Tucson, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 29, 2026, 5:59 AM EDT
Terminated Phase 2 Interventional Results available

Rucaparib in Nonmetastatic prOstAte With BRCAness

NCT03533946
View directory record Official record
Conditions
Prostate Cancer
Interventions
Rucaparib
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Sep 29, 2026, 5:59 AM EDT
Active, not recruiting Phase 2 Interventional

REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer

NCT03951831
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
REGN2810, Degarelix, Leuprolide Acetate, Docetaxel
Drug
Lead sponsor
Mark Stein
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Sep 29, 2026, 5:59 AM EDT
Recruiting Phase 1 Interventional

Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

NCT07140900
View directory record Official record
Conditions
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Interventions
Xaluritamig, Darolutamide, Abiraterone
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
8
States / cities
San Francisco, California • Boston, Massachusetts • Minneapolis, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 29, 2026, 5:59 AM EDT
Recruiting Phase 1 Interventional

Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer

NCT05997615
View directory record Official record
Conditions
Hormone-refractory Prostate Cancer
Interventions
VIR-5500, Androgen receptor signaling inhibitor (ARSI)
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
437 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
Orange, California • Palo Alto, California • Houston, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 29, 2026, 5:59 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)

NCT04191096
View directory record Official record
Conditions
Metastatic Hormone-Sensitive Prostate Cancer
Interventions
Pembrolizumab, Enzalutamide, Androgen Deprivation Therapy (ADT), Placebo
Biological · Drug · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
27
States / cities
Anchorage, Alaska • Duarte, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2026 · Synced Sep 29, 2026, 5:59 AM EDT
Completed Phase 2 Interventional Results available

Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer

NCT01875250
View directory record Official record
Conditions
Prostate Cancer
Interventions
PROSTVAC-F (Fowlpox)/TRICOM, PROSTVAC-V (Vaccinia)/TRICOM, Enzalutamide (Xtandi)
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced Sep 29, 2026, 5:59 AM EDT